Early development service for microbial fermentation

Early development service for microbial fermentation
Product Description

High throughput process development services for E. coli and yeast based on high degree of automation and digitalization to speed up time to clinic for diverse protein formats e.g., scaffolds, enzymes, pDNA, sub-unit vaccines and antibody fragments. Service description: - Genetic engineering, cell line and strain development for E.coli and Yeast hosts - High-density fermentation with E. coli expression systems - Soluble expression in E. coli with increased titers for Fabs - Inclusion body, refolding and HPLC both at clinical and commercial scale for purification steps - Caspon™ technology platform for purification - Half-life extension through chemical modifications, e.g. PEGylation - Proprietary plasmid DNA platform - AI-based modeling platform; machine-learning and integrated process modelling to derive best overall process

Boehringer Ingelheim Biopharmaceuticals GmbH

  • DE
  • 2023
    On CPHI since
  • 5000+
    Employees
Company types
CMO/CDMO

Boehringer Ingelheim Biopharmaceuticals GmbH

  • DE
  • 2023
    On CPHI since
  • 5000+
    Employees
Company types
CMO/CDMO

More Products from Boehringer Ingelheim Biopharmaceuticals GmbH (5)

  • Downstream Only - Processing for microbial derived proteins

    Product Downstream Only - Processing for microbial derived proteins

    Proven track record in ‘downstream- processing- only’ services Service description: - Intermediate materials, that need to be further purified and/or conjugated - Hormones or other recombinant proteins like virus like particles from inclusion bodies or from biomass - Peptides from inclusion bodies, biom...
  • Tech Transfer

    Product Tech Transfer

    Efficient tech transfers from customers or within own global bio-manufacturing network, launch preparation and commercial supply readiness for drug substance and drug product. Service description: - Long-standing track record in product launches - 47 biopharmaceuticals brought to the market - Tailored to...
  • Drug Substance Manufacturing - Mammalian Cell Cultures

    Product Drug Substance Manufacturing - Mammalian Cell Cultures

    • Around 430,000 L total commercial capacity for cell culture  • Manufacturing sites around the globe: Biberach/Germany, Vienna/Austria, Fremont, CA/USA and Shanghai/ China- from 2,000 up to 15,000 L bioreactors  • GMP facilities licensed by EMA, FDA, MHLW and other authorities ...
  • Drug Substance Manufacturing - Microbial Fermentation

    Product Drug Substance Manufacturing - Microbial Fermentation

    12,000 L  commercial manufacturing capacity in multi-licensed facility  Two trains  each with 6,000 L of capacity which can be used with flexible scales
    Large-scale GMP facilities licensed by EMA, FDA & MHLW for clinical and commercial global supplies 
    Protein refol...
  • Aseptic Filling

    Product Aseptic Filling

    • Clinical and commercial capacities and technology for vials  • Formulations for liquids and lyophilizates vials (flexible vial sizes from 2 mL to 100 mL) • Flexible filling volumes for clinical and commercial supply  • Manual and automated visual inspections  • Globally licensed ...

Boehringer Ingelheim Biopharmaceuticals GmbH resources (2)